Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0

作者：

Prezotti, A. ^{[1
,2
]}

Montalvao, S. ^{[1
]}

Marques, A. ^{[3
]}

Ferreira, C. ^{[4
]}

Oliveira, L. ^{[5
]}

Villaca, P. ^{[6
]}

Ferreira Filho, L. ^{[7
]}

Lorenzato, C. ^{[8
]}

Medina, S. ^{[1
]}

Araujo, F. ^{[9
]}

Ozelo, M. ^{[1
]}

机构：

[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil

[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil

[3] HEMORIO, Hematol, Rio De Janeiro, Brazil

[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil

[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil

[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil

[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil

[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil

[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO286-MON

引用

页码：366 / 366

页数：1

共 50 条

[41] Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF-beta as an immunomodulatory component in plasma-derived factor VIII concentrate
Hodge, G
Flower, R
Han, P
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) : 784 - 791
[42] Factor-VIII-inhibitor-bypassing-fraction/Recombinant-factor-VIIaLack of efficacy
Reactions Weekly, 2024, 2004 (1) : 208 - 208
[43] Factor VIII Inhibitor Bypass Activity and Recombinant Activated Factor VII in Cardiac Surgery
Rao, Vidya K.
Lobato, Robert L.
Bartlett, Blake
Klanjac, Mark
Mora-Mangano, Christina T.
Soran, P. David
Oakes, Daryl A.
Hill, Charles C.
van der Starre, Pieter J.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2014, 28 (05) : 1221 - 1226
[44] CONTROL OF HEMOSTASIS WITH RECOMBINANT FACTOR-VIIA IN PATIENT WITH INHIBITOR TO FACTOR-VIII
INGERSLEV, J
FELDSTEDT, M
SINDETPEDERSEN, S
LANCET, 1991, 338 (8770): : 831 - 832
[45] Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
Iorio, A.
Halimeh, S.
Holzhauer, S.
Goldenberg, N.
Marchesini, E.
Marcucci, M.
Young, G.
Bidlingmaier, C.
Brandao, L. R.
Ettingshausen, C. E.
Gringeri, A.
Kenet, G.
Knoefler, R.
Kreuz, W.
Kurnik, K.
Manner, D.
Santagostino, E.
Mannucci, P. M.
Nowak-Goettl, U.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) : 1256 - 1265
[46] DETERMINATION OF ANTI-FACTOR-VIII ANTIBODIES RESPONSIBLE FOR THE INHIBITOR TITTER IN HEMOPHILIACS TREATED WITH PLASMA OR RECOMBINANT FACTOR-VIII AND IN SPONTANEOUS INHIBITORS
SCANDELLA, D
NAKAI, H
FELCH, M
PRESCOTT, R
BRAY, G
HURST, D
BLOOD, 1994, 84 (10) : A240 - A240
[47] Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
Neufeld, Ellis J.
Sidonio, Robert F., Jr.
O'Day, Ken
Runken, M. Chris
Meyer, Kellie
Spears, Jeffrey
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 762 - 769
[48] Effect of recombinant and plasma-derived von Willebrand Factor on the procoagulant activity of factor VIII in thrombin generation assays
Knappe, Sabine
Till, Susanne
Scheiflinger, Friedrich
Dockal, Michael
HAEMOPHILIA, 2014, 20 : 28 - 28
[49] ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES
O'Day, K.
Runken, M. C.
Meyer, K. L.
Spears, J. B.
VALUE IN HEALTH, 2017, 20 (05) : A216 - A217
[50] COPPER-ATOM IDENTIFICATION IN THE DIFFERENT ACTIVE AND INACTIVE FORMS OF RECOMBINANT FACTOR-VIII-DELTA-II AND PLASMA-DERIVED FACTOR-VIII
BIHOREAU, N
RAMON, C
PIN, S
FONTAINEAUPART, MP
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1215 - 1215

← 1 2 3 4 5 →